{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:11:18Z","timestamp":1762956678914},"reference-count":25,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, MA, USA"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2021,9,2]]},"DOI":"10.1080\/17474086.2021.1942831","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T07:11:57Z","timestamp":1626678717000},"page":"867-875","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed\/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma"],"prefix":"10.1080","volume":"14","author":[{"given":"Yuqin","family":"Song","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Beijing Cancer Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai East Hospital, Tongji University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Sun-Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Hospital of Jilin University, Changchun City, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University Third Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jifeng","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province People\u2019s Hospital, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Kinley","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030421"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2019.04.01"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21438"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.801"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701002"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2016.1122514"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780049"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.85"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1037"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110608"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"cit0015","unstructured":"US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 [Internet] 2010 [cited 2020 Oct 14]. Available from: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf."},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12435"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2615"},{"issue":"9","key":"cit0018","first-page":"926","volume":"85","author":"Zinzani PL","year":"2000","journal-title":"Haematologica"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.017"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23237"},{"key":"cit0021","unstructured":"European Medicines Agency. ADCETRIS\u00ae (brentuximab vedotin) summary of product characteristics [Internet] 2018 [cited 2020 Oct 14]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adcetris-epar-product-information_en.pdf."},{"key":"cit0022","unstructured":"ADCETRIS\u00ae (brentuximab vedotin) for injection, for intravenous use [prescribing information]. Bothell, WA: Seattle Genetics Inc. 2019."},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1530"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2021.1942831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T17:52:01Z","timestamp":1631382721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2021.1942831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,2]]}},"alternative-id":["10.1080\/17474086.2021.1942831"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2021.1942831","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}